Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Fatty acid increases performance of cellular powerhouse

  • Geography, skills, local companies affect higher education impact on economic development

  • Early evidence suggests hybrid cochlear implants may benefit millions with common form of hearing loss

  • Practice doesn't always make perfect (depending on your brain)

  • National study of deep brain stimulation for depression fails to demonstrate efficacy

  • Specific cardiovascular risk factors may predict Alzheimer's disease

  • Brain disease scenarios revised by step-by-step imaging of toxic aggregation

  • Mobile stroke treatment units may greatly improve survival rates, chance of recovery for ischemic stroke patients

  • Sausage or broccoli on your pizza? How decision frames influence people's food orders

  • Some stroke treatments proven to reduce health care costs

  •